

MAYNE PHARMA OFFICIALLY OPENS NEWLY EXPANDED MANUFACTURING FACILITY

16 December 2025, Adelaide, Australia: Mayne Pharma Group Limited (**Mayne Pharma**) (ASX: MYX), today announces the official inauguration of the expanded Manufacturing Facility located in Salisbury, South Australia.

The event at Salisbury held today is officiated by The Hon Joe Szakacs MP, Minister for Trade and Investment in South Australia, and The Hon Zoe Bettison MP, Minister for Tourism and Multicultural Affairs in in South Australia, along with other invited dignitaries.

The GMP, FDA and TGA accredited facility occupies a 12 hectare site and is built for large scale production of solid oral and topical dosage forms including tablets, capsules, powders, pellets, liquids and creams. Over the past two years Mayne Pharma has invested approximately \$18 million to modernise and expand this plant by adding a new high-speed encapsulation suite and other automation upgrades. These improvements have substantially boosted production efficiency and quality.

The modernisation program was supported by a \$4.8 million Federal Government Modern Manufacturing Initiative (MMI) Grant, with the full funding having been received by June 2025. The completion of the upgraded facility provides Mayne Pharma with significantly expanded manufacturing capacity and capability, which includes serialisation capability, to support new product launches and exports from the site.

In FY25, the Mayne Pharma International segment delivered a 7% increase in revenues to \$75.6 million, gross profit increased by 1% to \$21.5 million and direct contribution was \$7.4 million.¹

New Bottling Line Installation



Source: Mayne Pharma

¹ See ASX announcement dated 29 August 2025

New Blister Pack Installation



Source: Mayne Pharma

- ENDS -

Authorised for release to the ASX by the Board Chair.

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.